Related Experiment Video

Updated: Jul 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A

Laurence Collette, Marc Buyse, Tomasz Burzykowski

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |December 11, 2007
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 2, 2013

    Related Experiment Videos

    Last Updated: Jul 9, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 2, 2013

    Related Concept Videos

    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
    Comparing the Survival Analysis of Two or More Groups01:20

    Comparing the Survival Analysis of Two or More Groups

    Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

    Articles linked to this work by shared authors, journal, and citation graph.

    Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.

    NPJ breast cancer·2026

    Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).

    The oncologist·2026

    Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

    Innovative oncology trial designs: Time to act - A review with recommendations of the Cancer Drug Development Forum.

    Journal of cancer policy·2025

    Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

    JAMA oncology·2025

    Regional variation in clinical-trial risks: a large-scale analysis of 585 clinical trials.

    BMJ open·2025

    Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us